Victory Capital Management Inc. Sells 260 Shares of Guardant Health, Inc. (NASDAQ:GH)

Victory Capital Management Inc. lessened its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 1.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,578 shares of the company’s stock after selling 260 shares during the quarter. Victory Capital Management Inc.’s holdings in Guardant Health were worth $445,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Lord Abbett & CO. LLC acquired a new position in Guardant Health during the 3rd quarter valued at approximately $15,624,000. Guyasuta Investment Advisors Inc. acquired a new position in Guardant Health during the 4th quarter valued at approximately $206,000. Cerity Partners LLC increased its stake in Guardant Health by 54.6% during the 3rd quarter. Cerity Partners LLC now owns 195,008 shares of the company’s stock valued at $4,473,000 after purchasing an additional 68,883 shares in the last quarter. Geode Capital Management LLC increased its stake in Guardant Health by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock valued at $64,754,000 after purchasing an additional 29,686 shares in the last quarter. Finally, Entropy Technologies LP acquired a new position in Guardant Health during the 4th quarter valued at approximately $377,000. Institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Raymond James reaffirmed an “outperform” rating and issued a $59.00 price objective (up from $39.00) on shares of Guardant Health in a report on Friday, February 21st. JPMorgan Chase & Co. upped their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Canaccord Genuity Group upped their price objective on shares of Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a report on Monday, February 24th. The Goldman Sachs Group upped their price objective on shares of Guardant Health from $49.00 to $56.00 and gave the company a “buy” rating in a report on Friday, February 21st. Finally, Guggenheim reaffirmed a “buy” rating and issued a $56.00 price objective on shares of Guardant Health in a report on Monday, February 24th. Twenty investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $48.40.

Guardant Health Stock Up 3.1 %

GH opened at $46.10 on Friday. The company has a market cap of $5.69 billion, a price-to-earnings ratio of -12.95 and a beta of 1.50. Guardant Health, Inc. has a 52-week low of $15.81 and a 52-week high of $50.89. The firm’s fifty day simple moving average is $43.85 and its two-hundred day simple moving average is $33.57.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The company had revenue of $201.81 million for the quarter, compared to analysts’ expectations of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. On average, research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.